The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity meeting the case definition for the primary efficacy analysis occurring from 14 days after the 2nd dose in the initial set of vaccination in SARS-CoV-2 naive participants in the LVRNA009 (50 µg) dose group.

The person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19 of any severity meeting the case definition for the primary efficacy analysis occurring from 14 days after the 2nd dose in the initial set of vaccination in SARS-CoV-2 naive participants in the LVRNA009 (50 µg) dose group.